Trial · NCT02138916
Results by group127
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 127
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | 1.19 | 95% Confidence Interval 1.04 to 1.36 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | 1.03 | 95% Confidence Interval 0.9 to 1.19 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | Placebo | 1.24 | 95% Confidence Interval 1.08 to 1.42 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | Benralizumab 30 mg | 1.4 | 95% Confidence Interval 1.19 to 1.64 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | Benralizumab 100 mg | 1.32 | 95% Confidence Interval 1.12 to 1.56 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | Placebo | 1.30 | 95% Confidence Interval 1.11 to 1.52 | Exacerbations per year | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | 0.014 | Standard Deviation 0.282 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | 0.031 | Standard Deviation 0.294 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | Placebo | 0.010 | Standard Deviation 0.275 | Liter | |
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | -5.025 | Standard Deviation 14.677 | Percentage | |
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | -6.723 | Standard Deviation 15.723 | Percentage | |
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | Placebo | -3.913 | Standard Deviation 15.039 | Percentage | |
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | -1.50 | Standard Deviation 6.89 | Score on a scale | |
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | -2.43 | Standard Deviation 6.34 | Score on a scale | |
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | Placebo | -1.22 | Standard Deviation 6.53 | Score on a scale | |
| Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | -1.085 | Standard Deviation 5.273 | Score on a scale | |
| Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | -1.354 | Standard Deviation 5.599 | Score on a scale | |
| Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL | Placebo | -0.504 | Standard Deviation 5.674 | Score on a scale | |
| Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | -0.05 | Standard Deviation 3.21 | Puffs/day | |
| Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | -0.27 | Standard Deviation 2.71 | Puffs/day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02138916/results